Pefloxacin in the treatment of severe infections in gynecological cancer patients

S. Scalambrino, M. Colombo, L. Negri, A. Maggioni, R. Milani

Research output: Contribution to journalArticlepeer-review


Infections often complicate the medical or surgical treatment of hospitalized cancer patients. In these cases, a broad-spectrum antibiotic treatment is necessary before the microbiological results are available. The aim of the present study is to verify the efficacy of pefloxacin as empirical antibiotic therapy in controlling infectious complications induced by surgery, chemotherapy or radiotherapy in female patients with gynecological cancer. To this purpose, 58 hospitalized patients with gynecologic malignancy and severe infectious complications were treated with intravenous pefloxacin at the dosage regimen of 400 mg every 12 hours. In all, 49 (or 91%) of the 54 evaluable patients were cured. The mean duration of successful treatment was 5.9±2.1 days (ranging 4-13 days). No side effects or clinical laboratory abnormalities requiring reduction or discontinuation of therapy were observed. We conclude that pefloxacin may be considered a first choice, broad-spectrum, single antibiotic for use in the empirical therapy of infections in gynecological cancer patients.

Original languageEnglish
Pages (from-to)257-264
Number of pages8
JournalJournal of Chemotherapy
Issue number4
Publication statusPublished - 1994


  • antiblastic chemotherapy
  • febrile morbidity
  • fever of unknown origin
  • gynecological cancer
  • pefloxacin
  • surgical infections

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)


Dive into the research topics of 'Pefloxacin in the treatment of severe infections in gynecological cancer patients'. Together they form a unique fingerprint.

Cite this